Circulating tumor DNA monitoring for cervical and anal cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial uses a blood test to track tumor DNA in patients with HPV-related cervical or anal cancer. It aims to see if this test can detect early signs of recurrence after radiation therapy, helping guide follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have anal canal or cervical cancer with HPV.
- Your cancer is locally confined or has spread only to nearby areas (stages I–III for anal or I B2–IV A for cervical).
- You will receive radiation therapy, with or without chemotherapy, as your main treatment.
- You are 18 years or older and in generally good health (ECOG score 0–1).
- If you have HIV, your CD4 count must be 200 or higher.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether tumor samples contain HPV DNA (genetic material from the HPV virus). The goal is to improve detection in anal and cervical cancers, especially in patients planning standard radiation treatment.
This trial tests whether adding an immunotherapy drug (retifanlimab) to standard chemoradiation improves outcomes for people with locally advanced anal cancer. The treatment is adjusted based on HPV DNA levels in your blood.
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
This study tests whether regular blood tests looking for “tumor DNA” can help guide your follow-up care after anal cancer treatment. It may help doctors decide what type of monitoring you need during check-ups.
This trial tests a personalized blood test that looks for tumor DNA to monitor cervical cancer and help guide treatment decisions. It is for people with advanced or returning cervical cancer who haven't started treatment yet.
This trial checks how well cervical cancer responds to surgery, radiation, and chemotherapy by measuring HPV DNA and RNA in blood and cervical mucus. It aims to improve monitoring during treatment.
Hear when a new HPV-Related Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.